|
Published by: Global Markets Direct
Published: Apr. 19, 2012 - 45 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Systemic Juvenile Idiopathic Arthritis (SJIA) Overview
- Therapeutics Development
- An Overview of Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA)
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Development by Companies
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Products under Development by Companies
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development
- Johnson & Johnson
- XOMA Ltd.
- Italfarmaco S.p.A.
- UCB S.A.
- Systemic Juvenile Idiopathic Arthritis (SJIA) – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Cimzia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Anakinra - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Givinostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Simponi - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Methotrexate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Drug Profile Updates
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Dormant Products
- Systemic Juvenile Idiopathic Arthritis (SJIA) – Product Development Milestones
- Featured News & Press Releases
- Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
- Sep 28, 2011: Abbott Japan And Eisai Announce Launch Of Humira Prefilled Syringe 20mg/0.4mL
- Jul 01, 2011: Abbott And Eisai Receive Japanese Approval For Additional Indication And New Formulation Of Humira In Juvenile Idiopathic Arthritis
- Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA
- Oct 18, 2010: Roche Submits ACTEMRA/RoACTEMRA Supplemental Marketing Authorizations In US And Europe For Treatment Of Systemic Juvenile Idiopathic Arthritis
- Aug 30, 2010: Abbott Japan and Eisai Submit Application for Additional Indication of Humira, a Fully Human Anti-TNFalpha Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis in Japan
- Jun 15, 2010: TxCell Successfully Completes Preclinical Development of TX-RAD in Inflammatory Arthritis
- Nov 20, 2009: Roche Announces Phase III Clinical Study Results Of ACTEMRA In Children With Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
- Feb 22, 2008: Abbott got FDA approval for Humira(Adalimumab) indicated for the treatment of Polyarticular Juvenile Idiopathic Arthritis.
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2012
- Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) – Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Johnson & Johnson, H1 2012
- XOMA Ltd., H1 2012
- Italfarmaco S.p.A., H1 2012
- UCB S.A., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Drug Profile Updates
- Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2012
- Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) – Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
AbstractSystemic Juvenile Idiopathic Arthritis (SJIA) – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2012', provides an overview of the Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
- A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Systemic Juvenile Idiopathic Arthritis (SJIA) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
